Reduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells

Cancer Gene Therapy

Volumn 13, Issue 5, 2006, Pages 451-459

  Itamochi, H ^a,b,c   Yamasaki, F ^a,b   Sudo, T ^a,b   Takahashi, T ^a,b   Bartholomeusz, C ^a,b   Das, S ^a,b   Terakawa, N ^c   Ueno, N T ^a,b  

^a Breast Cancer Translational Research Laboratory   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

Bcl 2; Ionizing radiation; Radiation induced toxicity

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; DNA; PROTEIN BCL 2; PROTEIN P53; VIRUS VECTOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CELL STRAIN 3T3; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; FIBROBLAST; GENE CONSTRUCT; GENE CONTROL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IRRADIATION; LUNG; MOUSE; MUTATION; NONHUMAN; PLASMID; POLYOMA VIRUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; RADIATION INJURY; TRANSCRIPTION INITIATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; LUNG; MICE; MICE, INBRED STRAINS; NIH 3T3 CELLS; PLASMIDS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION INJURIES; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

ANIMALIA; CUCUMBER MOSAIC VIRUS; POLYOMAVIRUS;

EID: 33645855604     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700920     Document Type: Article

References (34)

1. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293: 293-297.
2. Pena LA, Fuks Z, Kolesnick RN. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res 2000; 60: 321-327.
3. Deng W, Viar MJ, Johnson LR. Polyamine depletion inhibits irradiation-induced apoptosis in intestinal epithelia. Am J Physiol Gastrointest Liver Physiol 2005; 289: G599-G606.
4. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6.
5. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 1993; 53: 4701-4714.
6. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879-888.
7. Kyprianou N, King ED, Bradbury D, Rhee JG. bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997; 70: 341-348.
8. Levine B, Huang Q, Isaacs JT, Reed JC, Griffin DE, Hardwick JM. Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature 1993; 361: 739-742.
9. Huang A, Fone PD, Gandour-Edwards R, White RW, Low RK. Immunohistochemical analysis of BCL-2 protein expression in renal cell carcinoma. J Urol 1999; 162: 610-613.
10. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000; 60: 2155-2162.
11. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 2000; 6: 3923-3931.
12. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22: 3551-3555.
13. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256: 827-830.
14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
15. Rehemtulla A, Hamilton AC, Taneja N, Fridman J, Juan TS, Maybaum J et al. A caspase-resistant form of Bcl-X(L), but not wild type Bcl-X(L), promotes clonogenic survival after ionizing radiation. Neoplasia 1999; 1: 63-70.
16. Rudner J, Belka C, Marini P, Wagner RJ, Faltin H, Lepple-Wienhues A et al. Radiation sensitivity and apoptosis in human lymphoma cells. Int J Radiat Biol 2001; 77: 1-11.
17. Froesch BA, Aime-Sempe C, Leber B, Andrews D, Reed JC. Inhibition of p53 transcriptional activity by Bcl-2 requires its membrane-anchoring domain. J Biol Chem 1999; 274: 6469-6475.
18. Mirkovic N, Voehringer DW, Story MD, McConkey DJ, McDonnell TJ, Meyn RE. Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene 1997; 15: 1461-1470.
19. Brustugun OT, Fladmark KE, Doskeland SO, Orrenius S, Zhivotovsky B. Apoptosis induced by microinjection of cytochrome c is caspase-dependent and is inhibited by Bcl-2. Cell Death Differ 1998; 5: 660-668.
20. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
21. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998; 281: 2027-2031.
22. Tepper AD, de Vries E, van Blitterswijk WJ, Borst J. Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis. J Clin Invest 1999; 103: 971-978.
23. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994; 79: 329-339.
24. Story MD, Voehringer DW, Malone CG, Hobbs ML, Meyn RE. Radiation-induced apoptosis in sensitive and resistant cells isolated from a mouse lymphoma. Int J Radiat Biol 1994; 66: 659-668.
25. Agarwal ML, Agarwal A, Taylor WR, Chernova O, Sharma Y, Stark GR. A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc Natl Acad Sci USA 1998; 95: 14775-14780.
26. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
27. Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo. Cancer Res 2002; 62: 7316-7327.
28. McIlwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 1994; 54: 3718-3722.
29. Aldridge DR, Radford IR. Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines. Cancer Res 1998; 58: 2817-2824.
30. Hwang JH, Lim SC, Kim YC, Park KO, Ahn SJ, Chung WK. Apoptosis and bcl-2 expression as predictors of survival in radiation-treated non-small-cell lung cancer. Inr J Radiat Oncol Biol Phys 2001; 50: 13-18.
31. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003; 3: 117-129.
32. Ahrendt SA, Hu Y, Buta M, McDermott MP, Benoit N, Yang SC et al. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst 2003; 95: 961-970.
33. Li S, Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther 1997; 4: 891-900.
34. Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther 1998; 5: 930-937.